Drug Profile
Iobenguane I-131 - Jubilant DraxImage
Alternative Names: 131I-metaiodobenzylguanidine; 131I-MIBG; I-131 meta-iodobenzylguanidine; Iobenguane I-131 MIBG; Iobenguane sulfate; m-Iodobenzylguanidine sulfateLatest Information Update: 09 Jul 2022
Price :
$50
*
At a glance
- Originator Jubilant DraxImage
- Developer Jubilant DraxImage; New Approaches to Neuroblastoma Therapy Consortium; University Hospital Southampton NHS Foundation Trust
- Class Antineoplastics; Guanidines; Imaging agents; Iodobenzenes; Radiopharmaceutical diagnostics; Small molecules; Sulfates
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Neuroblastoma
Most Recent Events
- 03 Jun 2022 Updated clinical data from a phase II trial in Neuroblastoma (In infants, In children, In adolescents, In adults, Second-line therapy or greater, Monotherapy) presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Neuroblastoma(In adolescents, In children, In infants, Second-line therapy or greater, In adults) in United Kingdom (IV, Infusion)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Neuroblastoma(In adolescents, In children, In infants, Second-line therapy or greater, In adults) in United Kingdom (IV, Injection)